The MDS Beacon™

For patients with low-risk myelodysplastic syndromes (MDS), a combination therapy of vitamins K2 and D3 may improve low red blood cell and low platelet counts, according to a Phase 2 clinical trial conducted by Japanese researchers and published in the journal Leukemia Research.

While treatment options exist for low-risk MDS patients, such as Revlimid (lenalidomide), Vidaza (azacitidine), and Dacogen (decitabine), patients are not always responsive to such therapies. Researchers, therefore, are always looking for treatment alternatives.

The Japanese researchers explored…

Patients with myelodysplastic syndromes who also have impaired kidney function can be treated with Vidaza or Dacogen, although dose adjustments will be needed in some cases, according to a study conducted by researchers at the University of Texas M.D. Anderson Cancer Center.

Elderly patients, the population most affected by myelodysplastic syndromes (MDS), frequently experience impaired kidney function. Vidaza (azacitidine) and Dacogen (decitabine) are the two standard drugs used for patients with MDS, acute myeloid leukemia (AML), and chronic…